Efgartigimod Treatment Increases Spending for CIDP Patients

A new study has found that introducing efgartigimod alfa as a treatment option in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are currently receiving subcutaneous immune globulin (IG) or intravenous IG would result in substantially increased spending in the treatment of CIPD.

FDA Approves Implantable Device to Treat RA Patients

SetPoint System, a neuroimmune modulation device, has been approved by the U.S. Food and Drug Administration to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response, loss of response or intolerance to one or more biological or targeted synthetic disease-modifying anti-rheumatic drugs.

Diagnosing and Treating Infant Botulism

Photo of newborn in a hospital bed

Since the approval of BabyBIG, the only treatment for this rare but life-threatening disease affecting infants mostly under 6 months, the mortality rate is now less than 15 percent.

Update on Rabies

Illustration of a rabies virus

Though mostly eradicated in the U.S., treatment for rabies must begin immediately with hyperimmune globulin and vaccines.